

**INFORME DE BÚSQUEDA SISTEMÁTICA DE EVIDENCIA  
DE LOS EFECTOS DESEABLES E INDESEABLES**

**Guía de Práctica Clínica Leucemia Crónica**

2018



## ÍNDICE

TABLA RESUMEN	2
ESTRATEGIA DE BÚSQUEDA	3
CRITERIOS DE INCLUSIÓN	3
RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS	4
Selección de las revisiones	4
Extracción de datos	4
Mapeo de la evidencia	4
Apéndice 1. Estrategias de búsqueda:	5
Apéndice 2. Diagrama de flujo PRISMA	7
Apéndice 3. Referencias seleccionadas	8

**TABLA RESUMEN**

<b>Problema de salud</b>	Leucemia Crónica
<b>ICD10</b>	C91.1
<b>Fecha de entrega</b>	01/12/2018
<b>Investigador responsable</b>	Gabriel Rada Giacaman
<b>Número de revisiones sistemáticas</b>	55
<b>Número de preguntas</b>	74
<b>L·OVE</b>	<i>Chronic lymphocytic leukemia</i>
<b>L·OVE URL</b>	<a href="https://love.epistemonikos.org/loves/5b72a08ec80dd46c8e5ecba5">https://love.epistemonikos.org/loves/5b72a08ec80dd46c8e5ecba5</a>

## ESTRATEGIA DE BÚSQUEDA

Se realizaron búsquedas en Epistemonikos, una base de datos exhaustiva de revisiones sistemáticas relevantes para la toma de decisiones en salud. La búsqueda de evidencia fue realizada en las siguientes bases de datos<sup>1</sup> con las estrategias descritas en el Apéndice 1.

1. Cochrane database of systematic reviews (CDSR)
2. Database of Abstracts of Reviews of Effectiveness (DARE)
3. HTA Database
4. PubMed
5. LILACS
6. CINAHL.
7. PsychINFO.
8. EMBASE.
9. EPPI-Centre Evidence Library
10. 3ie Systematic Reviews and Policy Briefs Campbell Library
11. Clinical Evidence.
12. SUPPORT Summaries
13. WHO Institutional Repository for Information Sharing
14. NICE public health guidelines and systematic reviews
15. ACP Journal Club.
16. Evidencias en Pediatría
17. The JBI Database of Systematic Reviews and Implementation Reports

## CRITERIOS DE INCLUSIÓN

Consideramos todas las revisiones sistemáticas que están sintetizando estudios primarios (tanto experimentales como observacionales) de acuerdo a la definición empleada por la Colaboración Cochrane y la declaración PRISMA.<sup>2</sup>

Una revisión elegible debe cumplir con los siguientes criterios operacionales:

1. Reporta una búsqueda en al menos una base de datos electrónica.
2. Reporta al menos uno de los siguientes criterios inclusión de los estudios:

---

<sup>1</sup> La actualización se realiza de manera semanal. Se encuentra disponible en la plataforma digital un sistema de alerta que permite informar a través de correo electrónico la publicación de nuevos estudios que dan respuesta a las preguntas definidas, de manera de mantener continuamente actualizada la evidencia.

<sup>2</sup> “Una revisión sistemática intenta recopilar toda la evidencia empírica para responder a una pregunta de investigación específica, que cumple con criterios previamente definidos. Utiliza métodos explícitos y sistemáticos, que se eligen con miras a minimizar el sesgo, de manera de entregar hallazgos confiables que permitan sacar conclusiones y tomar decisiones”.

- **Tipo de participantes:** Se incluyen todas las revisiones sistemáticas que resuman estudios que respondan la pregunta acerca de intervenciones para leucemia linfática crónica.
- **Tipo de desenlaces:** Se incluyen revisiones que presentan una síntesis (cuantitativa o cualitativa) de al menos un desenlace importante para el paciente u otra información relevante para tomar decisiones poblacionales o individuales acerca de intervenciones para leucemia linfática crónica.

## RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS

### SELECCIÓN DE LAS REVISIONES

Al menos dos revisores, de manera independiente, realizaron el cribado de los títulos y resúmenes para identificar los artículos relevantes. El texto completo de las revisiones potencialmente elegibles fue recuperado y evaluado, de manera independiente, para su inclusión final. Un tercer investigador resolvió cualquier discrepancia que pudiera haberse provocado entre los distintos revisores.

### MAPEO DE LA EVIDENCIA

Con el objetivo de generar un listado exhaustivo de todas las posibles preguntas relacionadas con el tópico del L-OVE: *leucemia linfática crónica*<sup>3</sup>, se realiza la agrupación de las revisiones resultantes en formato PICO, es decir: población, intervención, comparación y desenlace [*outcome*] utilizamos las siguientes fuentes:

1. Guías y documentos
2. Criterios de inclusión de las revisiones sistemáticas identificadas
3. Consulta con expertos
4. Retroalimentación de los usuarios

Como resultado final la plataforma incluye toda la evidencia disponible en revisiones sistemáticas y sus estudios primarios incluidos, segregada por nodos de evidencia que representan cada una de las preguntas priorizadas para actualización de la guía (Ver “Diagrama de flujo PRISMA” en Apéndice 2 y “Referencia Seleccionada” en Apéndice 3).

### ACTUALIZACIÓN – “LIVING”

Todas las búsquedas a través de esta plataforma se mantienen continuamente actualizada gracias a la tecnología implementada en el buscador de Epistemonikos y sus distintos colaboradores. Por lo cual, tanto la cantidad de revisiones, preguntas, entre otros datos cambian continuamente. Los datos presentados en este informe son los correspondientes a la fecha de entrega.

---

<sup>3</sup>Ver resultados de la búsqueda en: <https://love.epistemonikos.org/loves/5b72a08ec80dd46c8e5ecba5>



**APÉNDICE 1. ESTRATEGIAS DE BÚSQUEDA:<sup>4</sup>**

Cochrane Library - Cochrane database of systematic reviews (CDSR)

<http://www.thecochranelibrary.com>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*), in Title, Abstract, Keywords:  
Cochrane Reviews (Reviews NOT protocols)

Medline/PubMed - US National Library of Medicine

<http://www.ncbi.nlm.nih.gov/pubmed/>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND (MEDLINE[Title/Abstract]  
OR (systematic[Title/Abstract] AND review[Title/Abstract]) OR meta analysis[Publication  
Type])

EMBASE (Excerpta Medica dataBASE)

<http://www.embase.com>

Frequency of search: weekly  
chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND (meta-analysis.tw. OR  
systematic review.tw)

CINAHL (Cumulative Index to Nursing and Allied Health Literature)

<https://www.ebscohost.com/nursing/products/cinahl-databases/the-cinahl-database>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND ((TI meta analys\* or AB  
meta analys\*) or (TI systematic review or AB systematic review))

PsycINFO

<http://www.apa.org/pubs/databases/psycinfo>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND (meta-analysis OR search\*)

LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud)

<http://lilacs.bvsalud.org/en/>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND (tw:"revision sistematica"  
or tw:"revisao sistematica" or tw:"systematic review") or ((MH:"Literatura de Revisión como  
asunto" OR MH:"Metanálisis como asunto" OR PT:Revision OR PT:Metanálisis) and  
(TW:Metaanal\$ OR TW:"Meta-analysis" OR TW:"Meta-analise" OR TW:"Meta-analisis" OR  
TI:overview\$ or TW:"estudio sistematico" OR TW:"systematic study" OR TW:"estudo  
sistematico" OR TI:review OR TI:revisao OR TI:revision))

<sup>4</sup> No se aplican restricciones en base al idioma o estado de publicación.

DARE (Database of Abstracts of Reviews of Effectiveness) - Centre for Reviews and Dissemination, University of York

<http://www.crd.york.ac.uk/CRDWeb/>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*), in Any field: CRD assessed review (bibliographic)/ CRD assessed review (full abstract)

HTA

Database

<http://www.crd.york.ac.uk/CRDWeb/>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*), in Any field

The Campbell Collaboration Online Library

<https://www.campbellcollaboration.org/library.html>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*), in Title: Review

JBI Database of Systematic Reviews and Implementation Reports

<http://journals.lww.com/jbisrir/pages>


chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) AND (review OR meta\*), in All fields

EPPI-Centre Evidence Library

<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=56>

chronic\* AND lympho\* AND (leukem\* OR leukaem\* or leuc\*) All records in chronological list (<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=62>)



**APÉNDICE 2. DIAGRAMA DE FLUJO PRISMA**

### APÉNDICE 3. REFERENCIAS SELECCIONADAS

1. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R, Cochrane Haematologic Malignancies Group. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. *Cancer treatment reviews*. 2006;32(5):377-89. [www.epistemonikos.org/documents/067715107cc836a8a8cc92bc23bde8d28da9560e](http://www.epistemonikos.org/documents/067715107cc836a8a8cc92bc23bde8d28da9560e)
2. Ratterman M, Kruczek K, Sulo S, Shanafelt TD, Kay NE, Nabhan C. Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. *Leukemia research*. 2014;38(3):299-303. [www.epistemonikos.org/documents/08bba11f3f1bc6ccfa8d3dce926f373128d7388b](http://www.epistemonikos.org/documents/08bba11f3f1bc6ccfa8d3dce926f373128d7388b)
3. Richards S., Clarke M., Wheatley K., Peto R.. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. *Journal of the National Cancer Institute*. 1999;91(10):861-8. [www.epistemonikos.org/documents/111598a67e21095df403ce11004d497fe0d13e6d](http://www.epistemonikos.org/documents/111598a67e21095df403ce11004d497fe0d13e6d)
4. Wu Y, Wang Y, Gu Y, Xia J, Kong X, Qian Q, Hong Y. Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis. *Hematology (Amsterdam, Netherlands)*. 2017;22(10):1-7. [www.epistemonikos.org/documents/153e68ec40be820aab5be904771e8141c24fd5e6](http://www.epistemonikos.org/documents/153e68ec40be820aab5be904771e8141c24fd5e6)
5. Lang D, George C. Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: A systematic review. *JBHI library of systematic reviews*. 2010;8(16 Suppl):1-19. [www.epistemonikos.org/documents/17d0b61af43b5e48738c9c890da0e48edba51ece](http://www.epistemonikos.org/documents/17d0b61af43b5e48738c9c890da0e48edba51ece)
6. Sorigue M, Orna E, Sancho JM. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. *Leukemia & lymphoma*. 2018;59(11):1-10. [www.epistemonikos.org/documents/188bf46aacaf3e45edd906426a681f799f2822ba](http://www.epistemonikos.org/documents/188bf46aacaf3e45edd906426a681f799f2822ba)
7. Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. *Leukemia & lymphoma*. 2004;45(11):2239-45. [www.epistemonikos.org/documents/1e18f46a586130aa0aa4dd4155129fa24c7f474a](http://www.epistemonikos.org/documents/1e18f46a586130aa0aa4dd4155129fa24c7f474a)
8. Stephens JM, Gramegna P, Laskin B, Botteman MF, Pashos CL, HERQuLES, Bethesda, MD. Chronic lymphocytic leukemia: economic burden and quality of life: literature review. *American Journal of Therapeutics*. 2005;12(5):460-466. [www.epistemonikos.org/documents/1f772bd4652a4e63391ddf53fbd88475af3c6b37](http://www.epistemonikos.org/documents/1f772bd4652a4e63391ddf53fbd88475af3c6b37)
9. Messori A., Fadda V., Maratea D., Trippoli S.. First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis. *Annals of Hematology*. 2015;94((Messori A., andrea.messori.it@gmail.com; Fadda V.; Maratea D.; Trippoli S.) HTA Unit, ESTAV Toscana Centro, Regional Health Service, Firenze, Italy):1003-9. [www.epistemonikos.org/documents/248b105a998d1ab8dfb4cc98498493c1734dbc21](http://www.epistemonikos.org/documents/248b105a998d1ab8dfb4cc98498493c1734dbc21)
10. Skoetz N., Trivella M., Kreuzer K.-A., Collins G., Kohler N., Wolff R., Moons K., Estcourt L.J.. Prognostic models for chronic lymphocytic leukaemia: An exemplar systematic review and meta-analysis. *Cochrane Database of Systematic Reviews*. 2016;2016(1). [www.epistemonikos.org/documents/275467d34573587117d0883f0a5e3846d814fada](http://www.epistemonikos.org/documents/275467d34573587117d0883f0a5e3846d814fada)
11. Lang D., George C.. Acute adverse reactions of rapid rituximab infusion among adult patients with non-hodgkin lymphoma and chronic lymphocytic leukemia. *JBHI Library of Systematic Reviews*. 2015;9(1):1-30. [www.epistemonikos.org/documents/2b0383d0040f49bb47c6161f357d54b2d4b29299](http://www.epistemonikos.org/documents/2b0383d0040f49bb47c6161f357d54b2d4b29299)

12. Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. *Cancer treatment reviews*. 2013;39(4):340-9.  
[www.epistemonikos.org/documents/2cfcb450406b66429728160dbf02f5b1ad51dec0](http://www.epistemonikos.org/documents/2cfcb450406b66429728160dbf02f5b1ad51dec0)
13. Xiao J., Yin S., Liu S., Xie S., Li Y., Nie D., Ma L., Wang X., Wu Y.. Meta-analysis on safety of purine analogues alone or combined with cyclophosphamide in the treatment of chronic lymphocytic leukemia. *Journal of Leukemia and Lymphoma*. 2014;23(5):274-280.  
[www.epistemonikos.org/documents/2d4ecdcf7c70d68469c0908e1393e6ae4ebffebd](http://www.epistemonikos.org/documents/2d4ecdcf7c70d68469c0908e1393e6ae4ebffebd)
14. Nunes AA, da Silva AS, Souza KM, Koury CDNS, de Mello LM. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis. *Critical Reviews in Oncology/Hematology*. 2015;94((Nunes A.A., altacilio@fmrp.usp.br; da Silva A.S.; Koury C.D.N.S.; de Mello L.M.) Department of Social Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil):261-9.  
[www.epistemonikos.org/documents/2deff96d58544fa7942e21920e6d0d36f80d7eff](http://www.epistemonikos.org/documents/2deff96d58544fa7942e21920e6d0d36f80d7eff)
15. Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. *Clinical lymphoma, myeloma & leukemia*. 2018;18(8):508-518.e14.  
[www.epistemonikos.org/documents/3049ac7eb6e05d8a13c0ffd617d6f27fe86f7c93](http://www.epistemonikos.org/documents/3049ac7eb6e05d8a13c0ffd617d6f27fe86f7c93)
16. Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek, Andreas Engert. Alemtuzumab for patients with chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews*. 2012;2(2):CD008078.  
[www.epistemonikos.org/documents/349ede0a6ff41b57e18f112fcb8c5d9854f68435](http://www.epistemonikos.org/documents/349ede0a6ff41b57e18f112fcb8c5d9854f68435)
17. Vidal L, Gurion R, Ram R, Raanani P, Bairey O, Robak T, Gafter-Gvili A, Shpilberg O. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials. *Leukemia & lymphoma*. 2016;57(9):1-11.  
[www.epistemonikos.org/documents/41325864e7fab3d065c20586f636302d8d7f5cd5](http://www.epistemonikos.org/documents/41325864e7fab3d065c20586f636302d8d7f5cd5)
18. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. *Leukemia & lymphoma*. 2009;50(5):764-72.  
[www.epistemonikos.org/documents/5a35c84a06453d2fc28e7971135081a21b4b61d6](http://www.epistemonikos.org/documents/5a35c84a06453d2fc28e7971135081a21b4b61d6)
19. Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. *Cancer treatment reviews*. 2012;38(8):1004-11. [www.epistemonikos.org/documents/5d0ff61796023fd9d82b228a77174114a381f447](http://www.epistemonikos.org/documents/5d0ff61796023fd9d82b228a77174114a381f447)
20. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. *The Lancet. Oncology*. 2016;17(6):779-90.  
[www.epistemonikos.org/documents/608db17a1dedc29e6085ee9a51777a57bdb08df6](http://www.epistemonikos.org/documents/608db17a1dedc29e6085ee9a51777a57bdb08df6)
21. Ladyzynski P., Molik M., Foltynski P.. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. *Cancer Treatment Reviews*. 2015;41(2):77-93.  
[www.epistemonikos.org/documents/64bd770692c204df5e8f8c0df48f5bb61660b5c3](http://www.epistemonikos.org/documents/64bd770692c204df5e8f8c0df48f5bb61660b5c3)
22. Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies. *Melanoma research*. 2016;26(2):188-94.  
[www.epistemonikos.org/documents/692decf8e7c849e81f607f5e36302a8f32bf601e](http://www.epistemonikos.org/documents/692decf8e7c849e81f607f5e36302a8f32bf601e)

23. CLL Trialists' Collaborative Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. *Haematologica*. 2012;97(3):428-36.  
[www.epistemonikos.org/documents/6a82a9267bef958d59dbe680a95ff7bd67e07eca](http://www.epistemonikos.org/documents/6a82a9267bef958d59dbe680a95ff7bd67e07eca)
24. Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized Controlled Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. *Clinical lymphoma, myeloma & leukemia*. 2015;15(4):199-207.  
[www.epistemonikos.org/documents/72f5032c879f785184f95a6da7e25cb636b4a53e](http://www.epistemonikos.org/documents/72f5032c879f785184f95a6da7e25cb636b4a53e)
25. Rancea M., Skoetz N., Trelle S., Da Costa B.R., Engert A., Fischer K., Hallek M., Eichhorst B.. First-line treatment strategies for previously untreated patients with chronic lymphocytic leukaemia: Preliminary results of a network meta-analysis. *Haematologica*. 2014;58.  
[www.epistemonikos.org/documents/74b91b416fa23403479ab16718c63359663484ce](http://www.epistemonikos.org/documents/74b91b416fa23403479ab16718c63359663484ce)
26. Sava GP, Speedy HE, Houlston RS. Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis. *Leukemia & lymphoma*. 2014;55(1):160-7.  
[www.epistemonikos.org/documents/783b61ac0e56f9ac175faa7cef63219b0159c05f](http://www.epistemonikos.org/documents/783b61ac0e56f9ac175faa7cef63219b0159c05f)
27. Liang L, Zhao M, Zhu YC, Hu X, Yang LP, Liu H. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. *Annals of hematology*. 2016;95(9):1473-82.  
[www.epistemonikos.org/documents/7c5d6989ac238a73b6ac046c2c6c04d6ac241d70](http://www.epistemonikos.org/documents/7c5d6989ac238a73b6ac046c2c6c04d6ac241d70)
28. Lang DS, Hagger C, Pearson A. Safety of rapid rituximab infusion in adult cancer patients: A systematic review. *International journal of nursing practice*. 2011;17(4):357-69.  
[www.epistemonikos.org/documents/7fdefb07880b0ebaed8abacee42afadc48a6deab](http://www.epistemonikos.org/documents/7fdefb07880b0ebaed8abacee42afadc48a6deab)
29. Michael Steurer, Georg Pall, Sue Richards, Guido Schwarzer, Julia Bohlius, Richard Greil. Purine Antagonists for Chronic Lymphocytic Leukaemia. *Cochrane Database of Systematic Reviews*. 2006;(3):CD004270.  
[www.epistemonikos.org/documents/8514e29d522c001a06f01d7662e8327737e1d78a](http://www.epistemonikos.org/documents/8514e29d522c001a06f01d7662e8327737e1d78a)
30. Kharfan-Dabaja MA, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. *British journal of haematology*. 2007;139(2):234-42.  
[www.epistemonikos.org/documents/8bbe48cc1f3a2bf46b61b5cb20a63888e9c8e7d3](http://www.epistemonikos.org/documents/8bbe48cc1f3a2bf46b61b5cb20a63888e9c8e7d3)
31. Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling, Ofer Shpilberg. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews*. 2012;9(9):CD009045.  
[www.epistemonikos.org/documents/8bcd03775409d7e0a69e8dad2db01fc71b0b148f](http://www.epistemonikos.org/documents/8bcd03775409d7e0a69e8dad2db01fc71b0b148f)
32. Benner A., Mansouri L., Rossi D., Majid A., Willander K., Parker A., Bond G., Pavlova S., Nuckel H., Merkel O., Ghia P., Montserrat E., Kaderi M.A., Rosenquist R., Gaidano G., Dyer M.J.S., Soderkvist P., Linderholm M., Oscier D., Tvaruzkova Z., Pospisilova S., Duhren U., Greil R., Dohner H., Stilgenbauer S., Zenz T.. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: Results of an individual patient data-based meta-analysis. *Haematologica*. 2014;99(8):1285-1291.  
[www.epistemonikos.org/documents/8dbe5f89197f683c858be2d57ba43386c31cdb7f](http://www.epistemonikos.org/documents/8dbe5f89197f683c858be2d57ba43386c31cdb7f)
33. Silver SR, Hiratzka SL, Schubauer-Berigan MK, Daniels RD. Chronic lymphocytic leukemia radiogenicity: a systematic review. *Cancer causes & control : CCC*. 2007;18(10):1077-93.  
[www.epistemonikos.org/documents/8e65b5e9037fb4704181752efe7a520ccd46406f](http://www.epistemonikos.org/documents/8e65b5e9037fb4704181752efe7a520ccd46406f)
34. Reljic T., Kumar A., Djulbegovic B., Kharfan-Dabaja M.A.. Meta-analysis evaluating efficacy of high-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: Results do not justify this treatment approach. *Blood*.

- 2014;124(21).  
[www.epistemonikos.org/documents/9186f2f02dcb1fc0f9eabc19f03d52d69adfc09](http://www.epistemonikos.org/documents/9186f2f02dcb1fc0f9eabc19f03d52d69adfc09)
35. Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. *Bone marrow transplantation*. 2015;50(8):1069-74.  
[www.epistemonikos.org/documents/93686732a79e311b7d05d6ab3035f41b12304460](http://www.epistemonikos.org/documents/93686732a79e311b7d05d6ab3035f41b12304460)
36. Zhang Z, Chen S, Chen G, Zhang R, Li J, Qu J. SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: A meta-analysis. *Oncotarget*. 2017;8(41):69916-69923.  
[www.epistemonikos.org/documents/93e0fefa771f21b3e029bcd1afffa75c77b97b84](http://www.epistemonikos.org/documents/93e0fefa771f21b3e029bcd1afffa75c77b97b84)
37. Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. *Hematology/oncology and stem cell therapy*. 2018;11(2):63-74.  
[www.epistemonikos.org/documents/9e37ce42a1464c4fc02c3a3e745c9b8f58513e31](http://www.epistemonikos.org/documents/9e37ce42a1464c4fc02c3a3e745c9b8f58513e31)
38. He C., Liu Z., Ji J., Zhu H.. Prognostic significance of CD38 for chronic lymphocytic leukemia: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2017;10(3):4305-4312.  
[www.epistemonikos.org/documents/a0b3f62da83790677aeeed2a2e1fe9a76725dc9a](http://www.epistemonikos.org/documents/a0b3f62da83790677aeeed2a2e1fe9a76725dc9a)
39. Berndt S.I., Camp N.J., Skibola C.F., Vijai J., Wang Z., Gu J., Nieters A., Kelly R.S., Smedby K.E., Monnereau A., Cozen W., Cox A., Wang S.S., Lan Q., Teras L.R., Machado M., Yeager M., Brooks-Wilson A.R., Hartge P., Purdue M.P., Birmann B.M., Vajdic C.M., Cocco P., Zhang Y., Giles G.G., Zeleniuch-Jacquotte A., Lawrence C., Montalvan R., Burdett L., Hutchinson A., Ye Y., Call T.G., Shanafelt T.D., Novak A.J., Kay N.E., Liebow M., Cunningham J.M., Allmer C., Hjalgrim H., Adami H.-O., Melbye M., Glimelius B., Chang E.T., Glenn M., Curtin K., Cannon-Albright L.A., Diver W.R., Link B.K., Weiner G.J., Conde L., Bracci P.M., Riby J., Arnett D.K., Zhi D., Leach J.M., Holly E.A., Jackson R.D., Tinker L.F., Benavente Y., Sala N., Casabonne D., Becker N., Boffetta P., Brennan P., Foretova L., Maynadie M., McKay J., Staines A., Chaffee K.G., Achenbach S.J., Vachon C.M., Goldin L.R., Strom S.S., Leis J.F., Weinberg J.B., Caporaso N.E., Norman A.D., De Roos A.J., Morton L.M., Severson R.K., Riboli E., Vineis P., Kaaks R., Masala G., Weiderpass E., Chirlaque M.-D., Vermeulen R.C.H., Travis R.C., Southey M.C., Milne R.L., Albanes D., Virtamo J., Weinstein S., Clavel J., Zheng T., Holford T.R., Villano D.J., Maria A., Spinelli J.J., Gascoyne R.D., Connors J.M., Bertrand K.A., Giovannucci E., Kraft P., Krickler A., Turner J., Ennas M.G., Ferri G.M., Miligi L., Liang L., Ma B., Huang J., Crouch S., Park J.-H., Chatterjee N., North K.E., Snowden J.A., Wright J., Fraumeni J.F., Offit K., Wu X., De Sanjose S., Cerhan J.R., Chanock S.J., Rothman N., Slager S.L.. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*. 2016;7(no pagination):10933.  
[www.epistemonikos.org/documents/a86599a3721707639601b775d4d379eae48ae59e](http://www.epistemonikos.org/documents/a86599a3721707639601b775d4d379eae48ae59e)
40. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews*. 2012;11(4):CD008079.  
[www.epistemonikos.org/documents/b185ee1cf7020e5fd4fe36c60c2091f036d81c7a](http://www.epistemonikos.org/documents/b185ee1cf7020e5fd4fe36c60c2091f036d81c7a)
41. Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. *Blood*. 2016;127(14):1752-60.  
[www.epistemonikos.org/documents/b65c5f0926a0396e675ef43ea5a8968dffaac292](http://www.epistemonikos.org/documents/b65c5f0926a0396e675ef43ea5a8968dffaac292)
42. Zhao L, Xi Y.-M., Guo M., Chao R., Jin R.-R.. Effectiveness and safety of FCR regimen for chronic lymphocytic leukemia: A systematic review. *Chinese Journal of Evidence-Based Medicine*. 2011;11(11):1321-1326.  
[www.epistemonikos.org/documents/c2d41c92713da30584a689e23b6d07257f6cbc9e](http://www.epistemonikos.org/documents/c2d41c92713da30584a689e23b6d07257f6cbc9e)

43. Dora Lang, Cobie George. Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. *JBI Library of Systematic Reviews*. 2011;9(1):1-37.  
[www.epistemonikos.org/documents/c392646ea5a138e05864533e12f1070d3fe74ce5](http://www.epistemonikos.org/documents/c392646ea5a138e05864533e12f1070d3fe74ce5)
44. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. *Haematologica*. 2011;96(5):752-61.  
[www.epistemonikos.org/documents/d02b191d5832e2d85dc00a7c2d45b5b2dbe8c0a0](http://www.epistemonikos.org/documents/d02b191d5832e2d85dc00a7c2d45b5b2dbe8c0a0)
45. Liu Y, Wang Y, Yang J, Bi Y, Wang H. ZAP-70 in chronic lymphocytic leukemia: A meta-analysis. *Clinica chimica acta; international journal of clinical chemistry*. 2018;483:82-88.  
[www.epistemonikos.org/documents/d34843f683ce2272f2fca7a3337a718b1cd090dc](http://www.epistemonikos.org/documents/d34843f683ce2272f2fca7a3337a718b1cd090dc)
46. Puła A, Stawiski K, Braun M, Iskierka-Jażdżewska E, Robak T. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. *Leukemia & lymphoma*. 2018;59(5):1-11.  
[www.epistemonikos.org/documents/e0e2432bff91a93e46754752a4227e031e5acbcc](http://www.epistemonikos.org/documents/e0e2432bff91a93e46754752a4227e031e5acbcc)
47. Beauchemin C, Johnston JB, Lapierre MÈ, Aissa F, Lachaine J. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. *Current oncology (Toronto, Ont.)*. 2015;22(3):e148-56.  
[www.epistemonikos.org/documents/e5009aec44f8fd16dab6c75e0a9991e00d662b83](http://www.epistemonikos.org/documents/e5009aec44f8fd16dab6c75e0a9991e00d662b83)
48. Frey S, Blankart CR, Stargardt T. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. *PharmacoEconomics*. 2016;34(5):479-98.  
[www.epistemonikos.org/documents/e71fa261e7ee6306ee0df3ed11c1511faf487ba7](http://www.epistemonikos.org/documents/e71fa261e7ee6306ee0df3ed11c1511faf487ba7)
49. Städler N, Shang A, Bosch F, Briggs A, Goede V, Berthier A, Renaudin C, Leblond V. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. *Advances in therapy*. 2016;33(10):1814-1830.  
[www.epistemonikos.org/documents/e7a99a7ba95bbb22e2eb9f889a88b88f043ea3b9](http://www.epistemonikos.org/documents/e7a99a7ba95bbb22e2eb9f889a88b88f043ea3b9)
50. Lepretre S, Jäger U, Janssens A, Leblond V, Nikitin E, Robak T, Wendtner CM. The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. *Leukemia & lymphoma*. 2012;53(5):820-9.  
[www.epistemonikos.org/documents/ed2246354a24c780430f82e7f57c69afe627ebdb](http://www.epistemonikos.org/documents/ed2246354a24c780430f82e7f57c69afe627ebdb)
51. Molica S, Giannarelli D, Mirabelli R, Levato L, Shanafelt TD. Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. *Annals of hematology*. 2018;97(10):2005-2008.  
[www.epistemonikos.org/documents/f2a2013567922dbfb06d3a603d5b627328330fb4](http://www.epistemonikos.org/documents/f2a2013567922dbfb06d3a603d5b627328330fb4)
52. Robak T. Emerging drugs for rarer chronic lymphoid leukemias. *Expert opinion on emerging drugs*. 2008;13(1):95-118.  
[www.epistemonikos.org/documents/f6695ddff2eed14a349f5b4ce53b058ca355c96f](http://www.epistemonikos.org/documents/f6695ddff2eed14a349f5b4ce53b058ca355c96f)
53. Sorensen S, Wildgust M, Sengupta N, Trambitas C, Diels J, van Sanden S, Xu Y, Dorman E. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. *Clinical therapeutics*. 2017;39(1):178-189.e5.  
[www.epistemonikos.org/documents/fb3824163cb8e15349f70648148c2c93f8ccbd01](http://www.epistemonikos.org/documents/fb3824163cb8e15349f70648148c2c93f8ccbd01)
54. Xu Y, Fahrback K, Dorman E, Baculea S, Côté S, Sanden SV, Diels J. Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis. *Journal of comparative effectiveness research*. 2018;7(5):421-441.  
[www.epistemonikos.org/documents/fc4a3be97bc4771e1c3db81853843bdfe462b3bc](http://www.epistemonikos.org/documents/fc4a3be97bc4771e1c3db81853843bdfe462b3bc)
55. Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M,

Eichhorst B. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). *Haematologica*. 2015;100(11):1451-9.  
[www.epistemonikos.org/documents/fece3d0a561da08adcb3e3dc24dd0d17bdcd3606](http://www.epistemonikos.org/documents/fece3d0a561da08adcb3e3dc24dd0d17bdcd3606)